Join us on the latest episode! Our Guest: Simon Allen, Former CEO, Anebulo Pharmaceuticals

What you'll get out of this episode:

• Journey from biochemistry to sell-side biotech business development.
• Current treatment landscape for ACI and the limitations therein.
• Introduction to ANEB-001, a promising antidote aimed at the CB1 receptor to counter cannabinoid overload.
• Impact of synthetic cannabinoids and the silent peril they pose.
• Upcoming milestones: Finalization of Phase 2 data and optimistic outlook towards FDA outcomes.

*Since the recording of this episode Simon has moved onto new endeavors*

To learn more about Anebulo Pharmaceuticals: https://www.anebulo.com/

Our sponsors for this episode are:
Sage Growth Partners https://sage-growth.com/